Neptune Wellness Solutions Inc (NEPTF)
OTCMKTS: NEPTF · Delayed Price · USD
0.0310
-0.0015 (-4.62%)
May 3, 2024, 3:28 PM EDT - Market closed
NEPTF Revenue
Neptune Wellness Solutions had revenue of $39.11M in the twelve months ending December 31, 2023, down -24.78% year-over-year. Revenue in the quarter ending December 31, 2023 was $7.60M, a -37.75% decrease year-over-year. In the fiscal year ending March 31, 2023, Neptune Wellness Solutions had annual revenue of $52.62M with 7.82% growth.
Revenue (ttm)
$39.11M
Revenue Growth
-24.78%
P/S Ratio
0.00
Revenue / Employee
$782,296
Employees
50
Market Cap
132.84K
Revenue Chart
* The company reports in CAD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 52.62M | 3.82M | 7.82% |
Mar 31, 2022 | 48.80M | 13.40M | 37.84% |
Mar 31, 2021 | 35.40M | 13.22M | 59.58% |
Mar 31, 2020 | 22.18M | 3.85M | 21.01% |
Mar 31, 2019 | 18.33M | -2.40M | -11.59% |
Mar 31, 2018 | 20.73M | -14.38M | -40.95% |
Mar 31, 2017 | 35.11M | 18.14M | 106.86% |
Feb 29, 2016 | 16.97M | 5.67M | 50.18% |
Feb 28, 2015 | 11.30M | -3.32M | -22.70% |
Feb 28, 2014 | 14.62M | -4.84M | -24.86% |
Feb 28, 2013 | 19.46M | 5.12M | 35.67% |
Feb 29, 2012 | 14.34M | 1.91M | 15.32% |
Feb 28, 2011 | 12.44M | 2.94M | 30.94% |
Feb 28, 2010 | 9.50M | 1.80M | 23.39% |
Feb 29, 2008 | 7.70M | 1.60M | 26.31% |
Feb 28, 2007 | 6.09M | 910.85K | 17.57% |
May 31, 2006 | 5.18M | 1.55M | 42.85% |
May 31, 2005 | 3.63M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
NEPTF News
- 2 months ago - Neptune Appoints Interim President and CEO and Interim COO - Accesswire
- 2 months ago - Top Marijuana Stocks For Trading Today 2024 - MarijuanaStocks
- 2 months ago - Neptune Announces Decision of Nasdaq Hearings Panel To Delist Common Shares - Accesswire
- 2 months ago - Neptune Announces Michael Cammarata's Resignation Effective February 23, 2024 - Accesswire
- 2 months ago - 2 Top Marijuana Penny Stocks with High Momentum Before March 2024 - MarijuanaStocks
- 2 months ago - Neptune Puts Employees, Including Certain Key Executives, on Mandatory Unpaid Leave of Absence Beginning February 23, 2024 - Accesswire
- 2 months ago - Neptune Reports Fiscal Third Quarter 2024 Financial Results - Accesswire
- 3 months ago - Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics - Accesswire